| 货号 | AF1310-SP |
| 别名 | ATF; EC 3.4.21; EC 3.4.21.73; plasminogen activator, urokinase; PLAU; uPA; u-PA; U-plasminogen activator; urinary; Urokinase; urokinase-type plasminogen activator | 全称 | Urokinase-type Plasminogen Activator |
| 反应种属 | Human |
| 应用 | Western Blot(0.1 µg/mL) Immunohistochemistry(5-15 µg/mL) Immunoprecipitation(25 µg/mL) |
| 目标/特异性 | Detects human u-Plasminogen Activator in direct ELISAs and Western blots. |
| 使用方法 | Western Blot: 0.1 µg/mL Immunohistochemistry: 5-15 µg/mL Immunoprecipitation: 25 µg/mL |
| 来源 | Reconstitute at 0.2 mg/mL in sterile PBS. |
| 产品组分 |
| 供应商 | R&D Systems |
| Entrez Gene IDs | 5328 (Human); 18792 (Mouse) |
| 应用文献 | |
| R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions. ErbB2-enhanced invasiveness of H-Ras MCF10A breast cells requires MMP-13 and uPA upregulation via p38 MAPK signaling. | |
| 纯化方式 | Antigen Affinity-purified |
| 免疫原 | Mouse myeloma cell line NS0-derived recombinant human uPA Ser21-Leu432 Accession # P00749 |
| 生物活性 | Human |
| 标记 | Unconjugated |
| 溶解方法 | Reconstitute at 0.2 mg/mL in sterile PBS. |
| 背景 | uPA is a serine protease with an extremely limited substrate specificity, cleaving the sequence Cys-Pro-Gly-Arg560-Val561-Val-Gly-Gly-Cys in plasminogen to form plasmin (1). uPA is a potent marker of invasion and metastasis in a variety of human cancers associated with breast, stomach, colon, bladder, ovary, brain, and endometrium (2). For example, the combination (both low vs. either or both high) of uPA and its inhibitor, plasminogen activator inhibitor-1 (PAI-1), outperforms the single factors as well as other traditional prognostic factors with regard to risk group assessment for breast cancer, particularly in node-negative breast cancer (3). The human uPA is initially synthesized as 431 amino acid precursor with a N-terminal signal peptide (20 residues) (4-6). The single chain molecule is processed into a disulfide-linked two-chain molecule. The B chain starting at Ile179 corresponds to the catalytic domain. Two forms of the A chain exist, one starting at Ser21 (the long form) and the other at Lys156 (the short form). The resulting two-chain forms have different molecular weights (MW). The B chain is common for both forms whereas the long and short A chains are unique to the high and low MW forms, respectively. The long A chain contains an EGF-like domain, which is responsible for binding of the uPA receptor (uPAR). Both high and low MW forms exist in the purified recombinant human uPA. |
| 运输条件 | Blue Ice |
| 存放说明 | 4℃ |
| 参考文献 |
|
u-Plasminogen Activator (uPA)/ Urokinase in Human Breast Cancer Tissue. u-Plasminogen Activator (uPA)/Urokinase was detected in immersion fixed paraffin-embedded sections of human breast cancer tissue using Goat Anti-Human u-Plasminogen Activator (uPA)/Urokinase Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1310) at 15 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). View our protocol for Chromogenic IHC Staining of immersion fixed paraffin-embedded Tissue Sections. | |
u-Plasminogen Activator (uPA)/Urokinase in Human Breast Cancer Tissue. u-Plasminogen Activator (uPA)/Urokinase was detected in immersion fixed paraffin-embedded sections of human breast cancer tissue using Goat Anti-Human u-Plasminogen Activator (uPA)/Urokinase Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1310) at 10 µg/mL overnight at 4 °C. Before incubation with the primary antibody tissue was subjected to heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic (Catalog # CTS013). Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections. |
